{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:28:47Z","timestamp":1791340127859,"version":"4.3.1"},"reference-count":96,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bloodreviews.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.blre.2016.06.001","type":"journal-article","created":{"date-parts":[[2016,6,18]],"date-time":"2016-06-18T07:32:32Z","timestamp":1466235152000},"page":"453-459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances"],"prefix":"10.1016","volume":"30","author":[{"given":"T.","family":"Barbui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Gisslinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Finazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2016.06.001_bb0005","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.06.001_bb0010","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.06.001_bb0015","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1046\/j.1365-2141.2002.03688.x","article-title":"Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients","volume":"118","author":"Cervantes","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0020","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1001\/archinte.165.22.2651","article-title":"Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia","volume":"165","author":"Chim","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.blre.2016.06.001_bb0025","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","article-title":"In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology","volume":"124","author":"Barbui","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.06.001_bb0030","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2016.06.001_bb0035","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/leu.2013.380","article-title":"Rethinking the diagnostic criteria of polycythemia vera","volume":"28","author":"Barbui","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.06.001_bb0040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"CYTO-PV collaborative group. Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2016.06.001_bb0045","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ajh.23417","article-title":"Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management","volume":"88","author":"Tefferi","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0050","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood-2014-07-551929","article-title":"How I treat polycythemia vera","volume":"124","author":"Vannucchi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.06.001_bb0055","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-2141.2007.06741.x","article-title":"National Cancer Research Institute, myeloproliferative disorder subgroup, Ryan K; British Committee for Standards in Haematology. Amendment to the guideline for diagnosis and investigation of polycythaemia\/erythrocytosis","volume":"138","author":"McMullin","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0060","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bjh.13812","article-title":"Management of polycythaemia vera: a critical review of current data","volume":"172","author":"McMullin","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0065","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000084673","article-title":"Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia","volume":"113","author":"Thiele","year":"2005","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0070","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1309\/6BQ5K8LHVYAKUAF4","article-title":"The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the \u201cearly\u201d prepolycythemic phase of polycythemia vera and essential thrombocythemia","volume":"30","author":"Gianelli","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.blre.2016.06.001_bb0075","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/ajh.21543","article-title":"Prodromal myeloproliferative neoplasms: the 2008 WHO classification","volume":"85","author":"Kvasnicka","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0080","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1182\/blood.V83.3.744.744","article-title":"Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay","volume":"83","author":"Shih","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.06.001_bb0085","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ajh.23585","article-title":"Masked polycythemia vera (mPV): results of an international study","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0090","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajh.23617","article-title":"Masked polycythemia vera diagnosed according to WHO and BCSH classification","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0095","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ajh.23694","article-title":"Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0100","first-page":"317","article-title":"Diagnostic impact of bone marrow histopathology in polycythemia vera (PV)","volume":"20","author":"Thiele","year":"2005","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.blre.2016.06.001_bb0105","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11899-013-0186-x","article-title":"WHO classification of myeloproliferative neoplasms (MPN): a critical update","volume":"8","author":"Kvasnicka","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.blre.2016.06.001_bb0110","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/modpathol.2013.196","article-title":"Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"27","author":"Gianelli","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.blre.2016.06.001_bb0115","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2013-06-508416","article-title":"Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis","volume":"122","author":"Silver","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.06.001_bb0120","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/leu.2013.99","article-title":"Personalized management of essential thrombocythemia\u2014application of recent evidence to clinical practice","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.06.001_bb0125","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ajh.23895","article-title":"Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management","volume":"90","author":"Tefferi","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0130","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjh.13080","article-title":"A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera","volume":"167","author":"Lussana","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0135","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-11-393819","article-title":"Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome","volume":"119","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.06.001_bb0140","first-page":"9","article-title":"Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia","volume":"36","author":"Murphy","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0145","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","article-title":"Polycythemia vera: myths, mechanisms, and management","volume":"100","author":"Spivak","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.06.001_bb0150","series-title":"Polycythemia vera and the myeloproliferative disorders","first-page":"166","article-title":"Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia Vera study group","author":"Berk","year":"1995"},{"key":"10.1016\/j.blre.2016.06.001_bb0155","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ajh.23970","article-title":"Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis","volume":"90","author":"Barbui","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0160","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/leu.2014.35","article-title":"An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.06.001_bb0165","first-page":"1194","article-title":"Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis","volume":"89","author":"Mossuz","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2016.06.001_bb0170","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.06.001_bb0175","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","article-title":"Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes","volume":"111","author":"Wilkins","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.06.001_bb0180","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2559.2010.03545.x","article-title":"Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis","volume":"56","author":"Brousseau","year":"2010","journal-title":"Histopathology"},{"key":"10.1016\/j.blre.2016.06.001_bb0185","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.12990","article-title":"WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes","volume":"166","author":"Alvarez-Larran","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0190","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/leu.2015.87","article-title":"Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis","volume":"29","author":"Palandri","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.06.001_bb0195","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/leu.2013.74","article-title":"Problems and pitfalls regarding WHO-defined diagnosis of early\/prefibrotic primary myelofibrosis versus essential thrombocythemia","volume":"27","author":"Barbui","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.06.001_bb0200","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11899-009-0005-6","article-title":"The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis","volume":"4","author":"Thiele","year":"2009","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.blre.2016.06.001_bb0205","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/ajh.23554","article-title":"World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations \u2014 the Danish experience","volume":"88","author":"Madelung","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0210","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","article-title":"Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification","volume":"117","author":"Thiele","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.06.001_bb0215","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1038\/modpathol.2014.69","article-title":"High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms","volume":"27","author":"Pozdnyakova","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.blre.2016.06.001_bb0220","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/his.12871","article-title":"Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis \u2014 a consensus based study","volume":"68","author":"Kvasnicka","year":"2016","journal-title":"Histopathology"},{"key":"10.1016\/j.blre.2016.06.001_bb0225","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2016.06.001_bb0230","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000083452","article-title":"The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies","volume":"113","author":"Kreft","year":"2005","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0235","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2016.06.001_bb0240","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.06.001_bb0245","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/leu.2015.360","article-title":"Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria","volume":"30","author":"Gisslinger","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.06.001_bb0250","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1179\/1607845412Y.0000000023","article-title":"Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up","volume":"18","author":"Ejerblad","year":"2013","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2016.06.001_bb0255","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2016.06.001_bb0260","first-page":"29","article-title":"Experience of the polycythemia vera study group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment","volume":"34","author":"Murphy","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0265","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2141.2007.06807.x","article-title":"Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres","volume":"139","author":"Kuter","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0270","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.06.001_bb0275","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.seminoncol.2005.04.010","article-title":"Hematopathologic findings in chronic idiopathic myelofibrosis","volume":"32","author":"Thiele","year":"2005","journal-title":"Semin Oncol"},{"key":"10.1016\/j.blre.2016.06.001_bb0280","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00277-002-0604-y","article-title":"Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients","volume":"82","author":"Thiele","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0285","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2008.20.3174","article-title":"Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy","volume":"27","author":"Campbell","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2016.06.001_bb0290","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","article-title":"Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and JAK2 mutation status","volume":"109","author":"Carobbio","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.06.001_bb0295","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/ajh.23217","article-title":"Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early\/prefibrotic myelofibrosis: an international study of 264 patients","volume":"87","author":"Buxhofer-Ausch","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0300","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/(SICI)1096-8652(199804)57:4<277::AID-AJH2>3.0.CO;2-R","article-title":"Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: role of the lipoxygenase pathway","volume":"57","author":"Cortelazzo","year":"1998","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0305","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/cncr.20646","article-title":"Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile","volume":"101","author":"Steurer","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2016.06.001_bb0310","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/leu.2011.258","article-title":"Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria","volume":"26","author":"Finazzi","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.06.001_bb0315","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjh.12986","article-title":"Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia","volume":"167","author":"Harrison","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0320","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjh.12985","article-title":"Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology guidelines for investigation and management of myelofibrosis 2012","volume":"167","author":"Reilly","year":"2014","journal-title":"Br Haematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0325","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.06.001_bb0330","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2016.06.001_bb0335","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2016.06.001_bb0340","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.06.001_bb0345","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0350","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.06.001_bb0355","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.06.001_bb0360","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1038\/leu.2014.148","article-title":"Calreticulin mutations and long-term survival in essential thrombocythemia","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"127","key":"10.1016\/j.blre.2016.06.001_bb0365","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"21","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood"},{"issue":"127","key":"10.1016\/j.blre.2016.06.001_bb0370","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients","volume":"21","author":"Cabagnols","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.06.001_bb0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035631","article-title":"Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis","volume":"7","author":"Barosi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2016.06.001_bb0380","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.64","article-title":"Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2016.06.001_bb0385","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1046\/j.1365-2141.1999.01262.x","article-title":"The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia","volume":"104","author":"Barosi","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0390","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1080\/10428190600678975","article-title":"Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology","volume":"47","author":"Gianelli","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2016.06.001_bb0395","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/sj.leu.2401553","article-title":"Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) \u2014 a clinicopathological study","volume":"13","author":"Thiele","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.06.001_bb0400","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1309\/PTVGB3DXB8A8M7KD","article-title":"Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens","volume":"119","author":"Buhr","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.blre.2016.06.001_bb0405","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1080\/1042819031000077070","article-title":"Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients","volume":"44","author":"Thiele","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2016.06.001_bb0410","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00277-005-0042-8","article-title":"Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis","volume":"85","author":"Thiele","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0415","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.beha.2014.07.004","article-title":"Essential thrombocythemia vs. early\/prefibrotic myelofibrosis: why does it matter","volume":"27","author":"Barosi","year":"2014","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.blre.2016.06.001_bb0420","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1055\/s-2006-942757","article-title":"The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera","volume":"32","author":"Kvasnicka","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2016.06.001_bb0425","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood-2007-09-112953","article-title":"Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis","volume":"111","author":"Vener","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.06.001_bb0430","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Pasamonti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.06.001_bb0435","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/modpathol.2012.87","article-title":"The European consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis","volume":"25","author":"Gianelli","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.blre.2016.06.001_bb0440","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3324\/haematol.2014.109249","article-title":"Calreticulin mutations in Chinese with primary myelofibrosis","volume":"99","author":"Li","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2016.06.001_bb0445","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.06.001_bb0450","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3324\/haematol.2014.107482","article-title":"Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations","volume":"99","author":"Andrikovics","year":"2014","journal-title":"Haematologica"},{"issue":"124","key":"10.1016\/j.blre.2016.06.001_bb0455","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"14","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.06.001_bb0460","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.06.001_bb0465","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"issue":"124","key":"10.1016\/j.blre.2016.06.001_bb0470","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","article-title":"The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants","volume":"9","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.06.001_bb0475","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/leu.2014.83","article-title":"Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.06.001_bb0480","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X16300303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X16300303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T18:48:00Z","timestamp":1718650080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X16300303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":96,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0268960X16300303"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2016.06.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2016.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}